Skip to main content

Shih Lab Earns NeuroImage ‘Paper of the Year’ Honors

July 7, 2022
The lab of Ian Shih, PhD, received the top prize from the journal NeuroImage for brain research featuring fMRI and fast-scan cyclic voltammetry. First author was Lindsay Walton, PhD.

Neurology News – July 2022

July 4, 2022
What’s new in the Department of Neurology

Welcome to Our New Residents and Fellows 2022-2023

June 30, 2022
We are pleased to introduce our incoming adult and child neurology residents and fellows for FY2022.

Hunter named as American Epilepsy Society Sergievsky Scholar

June 27, 2022
Senyenne Hunter, MD, PhD, is one of two recipients who are the first grantees to receive the award.

Powers to Retire from UNC after 15 years of Service

June 15, 2022
William J. Powers, MD, Professor of Neurology and former department chair (April 2007 – April 2018) to retire on June 30.

Neurology News – May 2022

May 10, 2022
What’s new in the Department of Neurology

Scientists Detail Brain Dynamics Implicated in Neurological Conditions

May 5, 2022
UNC School of Medicine researchers led by Ian Shih, PhD, used fMRI and a genetic mouse model to study the effects of a neurotransmitter on brain network functional connectivity, a dynamic process crucial for human health and behavior.

FDA Approves Treatment for Myasthenia Gravis After Phase III Study Led by James Howard, MD

May 5, 2022
James F. Howard, Jr, MD, in the UNC Department of Neurology is the lead primary investigator in the CHAMPION-MG trial for Ultomiris (ravulizumab-cwvz) as a treatment for adults with generalised myasthenia gravis who are anti-acetylcholine receptor antibody-positive, which represents 80% of people living with the disease.

Hunter named as Simmons Scholar

May 2, 2022
Dr. Senyene Hunter, assistant professor of child neurology, was named as a UNC School of Medicine Simmons Scholar, effective July 2022.

Interim Data Suggest Long-term Treatment with VYVGART Provides Improvement in Generalized Myasthenia Gravis Disease Scores

April 7, 2022
James F. Howard Jr., MD, professor in the UNC Department of Neurology, was principal investigator of the ADAPT+ trial for the experimental drug efgartigimod, developed by Belgian pharmaceutical company Argenx.